Kwas zoledronowy: interakcje

Pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. (etykieta leku Kwas pamidronowy, Przeciwwskazania)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

• Aminoglycosides: May lower serum calcium for prolonged periods ( 7.1 ) (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Use Reclast with caution in aspirin-sensitive patients. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Use Reclast with caution in aspirin-sensitive patients. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (etykieta leku Deferazyroks, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

In patients with renal impairment, the exposure to concomitant medications that are primarily renally excreted (e.g., digoxin) may increase. (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

All patients should be instructed about the symptoms of hypocalcemia and the importance of calcium and vitamin D supplementation in maintaining serum calcium levels [see Dosage and Administration ( 2.8 ), Adverse Reactions ( 6.1 ), Patient Counseling Information ( 17 )]. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

• Aminoglycosides: May lower serum calcium for prolonged periods ( 7.1 ) (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

All patients should be instructed about the symptoms of hypocalcemia and the importance of calcium and vitamin D supplementation in maintaining serum calcium levels [see Dosage and Administration ( 2.8 ), Adverse Reactions ( 6.1 ), Patient Counseling Information ( 17 )]. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

All patients should be instructed about the symptoms of hypocalcemia and the importance of calcium and vitamin D supplementation in maintaining serum calcium levels [see Dosage and Administration ( 2.8 ), Adverse Reactions ( 6.1 ), Patient Counseling Information ( 17 )]. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Closely monitor for signs of renal toxicity when XELODA is used concomitantly with nephrotoxic drugs (e.g. platinum salts, irinotecan, methotrexate, intravenous bisphosphonates). (etykieta leku Kapecytabina, Interakcje z innymi lekami)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Use Reclast with caution in aspirin-sensitive patients. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Use Reclast with caution in aspirin-sensitive patients. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Suplementy i leki zobojętniające kwas żołądkowy zawierające magnez zmniejszają wchłanianie tych leków; dawki należy rozdzielić odstępem co najmniej dwóch godzin. (NIH Office of Dietary Supplements, Magnesium)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

• Aminoglycosides: May lower serum calcium for prolonged periods ( 7.1 ) (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Oxybutynin chloride extended-release tablets should be used with caution in patients who have gastroesophageal reflux and/or who are concurrently taking drugs (such as bisphosphonates) that can cause or exacerbate esophagitis. (etykieta leku Oksybutynina, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Use Reclast with caution in aspirin-sensitive patients. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

All patients should be instructed about the symptoms of hypocalcemia and the importance of calcium and vitamin D supplementation in maintaining serum calcium levels [see Dosage and Administration ( 2.8 ), Adverse Reactions ( 6.1 ), Patient Counseling Information ( 17 )]. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

• Aminoglycosides: May lower serum calcium for prolonged periods ( 7.1 ) (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (etykieta leku Sunitynib, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

• Aminoglycosides: May lower serum calcium for prolonged periods ( 7.1 ) (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Nephrotoxic Drugs Caution is indicated when Reclast is used with other potentially nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs). (etykieta leku Kwas zoledronowy, Interakcje z innymi lekami)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Wapń wiąże te leki w jelicie i może znacznie ograniczyć wchłanianą ilość; dawki należy rozdzielić w czasie. (NIH Office of Dietary Supplements, Calcium)

All patients should be instructed about the symptoms of hypocalcemia and the importance of calcium and vitamin D supplementation in maintaining serum calcium levels [see Dosage and Administration ( 2.8 ), Adverse Reactions ( 6.1 ), Patient Counseling Information ( 17 )]. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Żelazo wiąże te leki w jelicie i zmniejsza ich wchłanianie; dawki należy rozdzielić w czasie. (NIH Office of Dietary Supplements, Iron)

Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (etykieta leku Eksemestan, Ostrzeżenia i środki ostrożności)

A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate [see Adverse Reactions ( 6.2 )] . (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate [see Adverse Reactions ( 6.2 )] . (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate [see Adverse Reactions ( 6.2 )] . (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Hypocalcemia and Mineral Metabolism Preexisting hypocalcemia and disturbances of mineral metabolism (e.g., hypoparathyroidism, thyroid surgery, parathyroid surgery; malabsorption syndromes, excision of small intestine) must be effectively treated before initiating therapy with Reclast. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Hypocalcemia and Mineral Metabolism Preexisting hypocalcemia and disturbances of mineral metabolism (e.g., hypoparathyroidism, thyroid surgery, parathyroid surgery; malabsorption syndromes, excision of small intestine) must be effectively treated before initiating therapy with Reclast. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Hypocalcemia and Mineral Metabolism Preexisting hypocalcemia and disturbances of mineral metabolism (e.g., hypoparathyroidism, thyroid surgery, parathyroid surgery; malabsorption syndromes, excision of small intestine) must be effectively treated before initiating therapy with Reclast. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Hypocalcemia and Mineral Metabolism Preexisting hypocalcemia and disturbances of mineral metabolism (e.g., hypoparathyroidism, thyroid surgery, parathyroid surgery; malabsorption syndromes, excision of small intestine) must be effectively treated before initiating therapy with Reclast. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Hypocalcemia and Mineral Metabolism Preexisting hypocalcemia and disturbances of mineral metabolism (e.g., hypoparathyroidism, thyroid surgery, parathyroid surgery; malabsorption syndromes, excision of small intestine) must be effectively treated before initiating therapy with Reclast. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)

Hypocalcemia and Mineral Metabolism Preexisting hypocalcemia and disturbances of mineral metabolism (e.g., hypoparathyroidism, thyroid surgery, parathyroid surgery; malabsorption syndromes, excision of small intestine) must be effectively treated before initiating therapy with Reclast. (etykieta leku Kwas zoledronowy, Ostrzeżenia i środki ostrożności)